1Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclopohsphamide, methotrexate,and fluororacil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the zoladex early breast cancer research association study. J Clin Oncol,2002,20:4628-4635.
2Mouridsen H, Gershanovich M,Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲstudy of the international letrozole breast cancer group. J Clin Oncol,2001,19:2596-2606.
3Bonneterre J, Thurlimann B, Robertson J. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol,2000,18:3748-3757.
4Nabholtz J, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol,2000,18:3758-3767.
5Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients- A randomized phaseⅢ trial of the EORTC Breast Group. Proc Am Soc Clin Oncol,2004,23:6.
6Eiermann W, Paepke S, Appfelstaedt J, et al. preoperative treatment of post-menopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol,2001,12:1527-1532.
8Robertson JFR, Willsher PC,Cheung KL, et al. The Clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer,1997,33:1774-1779.
9The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoifen alone for adjuvant treatment of postmnopausal women with early breast cancer: first results of the ATAC randmised trial. Lancet,2002,359:2131-2139.
10Goss PE, Lngle JM, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003,349:1793-1802.
